Head and Neck Tumors

Опухоли головы и шеи

2222-14682411-4634

Publishing House ABV Press

229

10.17650/2222-1468-2017-7-1-12-21

DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS

ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИ

The use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in patients with differentiated thyroid cancer after initial treatment

Основы применения совмещенной позитронно-эмиссионной и компьютерной томографии с 18-фтордезоксиглюкозой при дифференцированном раке щитовидной железы после первичного лечения

Geliashvili

T. M.

Гелиашвили

Т. М.

Russian Federation

42 Blyukhera St., Chelyabinsk 454087, Russia

Россия, 454087 Челябинск, ул. Блюхера, 42

geliashvili_tata@mail.ru

Vazhenin

A. V.

Важенин

А. В.

Russian Federation

42 Blyukhera St., Chelyabinsk 454087, Russia

Россия, 454087 Челябинск, ул. Блюхера, 42

Afanas’eva

N. G.

Афанасьева

Н. Г.

Russian Federation

42 Blyukhera St., Chelyabinsk 454087, Russia

Россия, 454087 Челябинск, ул. Блюхера, 42

Chelyabinsk Regional Clinical Oncology DispensaryГБУЗ «Челябинский областной клинический онкологический диспансер»

02042017

12213103201731032017

2017

Geliashvili T.M., Vazhenin A.V., Afanas’eva N.G.

Гелиашвили Т.М., Важенин А.В., Афанасьева Н.Г.

https://creativecommons.org/licenses/by/4.0

https://ogsh.abvpress.ru/jour/article/view/229

Establishment of new centers for nuclear medicine in our country made diagnostic and treatment procedures more accessible for patients with differentiated thyroid cancer (DTC). It includes radioiodine therapy, considered as a non-alternative method of treatment, and positron emission tomography combined with computed tomography (PET/CT), which is essential in some clinical cases. For many years suspected tumor relapse with increased level of thyroglobulin and negative radioiodine scan was the only indication for PET/CT use among patients with DTC. But over the last decade the indications for PET/CT use in DTC cases expanded significantly. This review is aimed to analyze currently available data on PET/CT in DTC patients, its indications for use, advantages and limitations, new trends and recommendations.

Благодаря открытию в нашей стране новых центров ядерной медицины для многих пациентов с дифференцированным раком щитовидной железы (ДРЩЖ) стал более доступным не только такой безальтернативный метод лечения, как радиойодтерапия, но и столь же незаменимый в некоторых клинических ситуациях метод обследования, как позитронно-эмиссионная томография, совмещенная с компьютерной томографией (ПЭТ / КТ). Многие годы единственным показанием к применению ПЭТ / КТ при ДРЩЖ считалось подозрение на рецидив опухоли, сопровождающийся повышенным уровнем тиреоглобулина и негативным радиойодсканом. Но за последнее десятилетие показания к применению ПЭТ / КТ при ДРЩЖ значительно расширились. Целью данной обзорной работы является анализ данных литературы, касающихся показаний, преимуществ и ограничений, новых тенденций и рекомендаций относительно применения ПЭТ / КТ при ДРЩЖ.

positron emission tomography combined with computed tomographydifferentiated thyroid cancer131I whole body scintigraphyradioiodine ablationthyroglobulin

позитронная-эмиссионная томографиясовмещенная с компьютерной томографиейдифференцированный рак щитовидной железысцинтиграфия всего тела с радиоактивным йодом-131радиойодабляциятиреоглобулин

1. Чиссов В.И., Дарьялова С.Л. Онкология. М.: ГЭОТАР-Медиа, 2007. [Chissov V.I., Daryalova S.L. Oncology. Moscow: GEOTAR-Media, 2007. (In Russ.)].

Чиссов В.И., Дарьялова С.Л. Онкология. М.: ГЭОТАР-Медиа, 2007. [Chissov V.I., Daryalova S.L. Oncology. Moscow: GEOTAR-Media, 2007. (In Russ.)].

2. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. [Malignant neoplasms in Russia in 2013 (morbidity and mortality). Eds. A.D. Kaprin, V.V. Starinsky, G.V. Petrova.Moscow, 2015. (In Russ.)].

Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. [Malignant neoplasms in Russia in 2013 (morbidity and mortality). Eds. A.D. Kaprin, V.V. Starinsky, G.V. Petrova.Moscow, 2015. (In Russ.)].

3. Sherman S.I. Thyroid carcinoma. Lancet 2003;361(9356):501–11. DOI: 10.1016/S0140- 6736(03)12488-9. PMID: 12583960

Sherman S.I. Thyroid carcinoma. Lancet 2003;361(9356):501–11. DOI: 10.1016/S0140- 6736(03)12488-9. PMID: 12583960

4. Sipos J.A., Mazzaferri E.L. Thyroid Cancer Epidemiology and Prognostic Variables. Clin Oncol (R Coll Radiol) 2010;22(6):395–404. DOI: 10.1016/j.clon.2010.05.004. PMID: 20627675

Sipos J.A., Mazzaferri E.L. Thyroid Cancer Epidemiology and Prognostic Variables. Clin Oncol (R Coll Radiol) 2010;22(6):395–404. DOI: 10.1016/j.clon.2010.05.004. PMID: 20627675

5. Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9. DOI: 10.1210/jc.2005-1322. PMID: 16263822

Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9. DOI: 10.1210/jc.2005-1322. PMID: 16263822

6. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973– 2002. JAMA 2006;295(18):2164–7. DOI: 10.1001/jama.295.18.2164. PMID: 16684987

Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973– 2002. JAMA 2006;295(18):2164–7. DOI: 10.1001/jama.295.18.2164. PMID: 16684987

7. Schonberger J., Ruschoff J., Grimm D. et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 2002;12(9):747–54. DOI: 10.1089/105072502760339307. PMID: 12481939

Schonberger J., Ruschoff J., Grimm D. et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 2002;12(9):747–54. DOI: 10.1089/105072502760339307. PMID: 12481939

8. Grabellus F., Nagarajah J., Bockisch A. et al. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012;37(2):121–7. DOI: 10.1097/RLU.0b013e3182393599. PMID: 22228332

Grabellus F., Nagarajah J., Bockisch A. et al. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012;37(2):121–7. DOI: 10.1097/RLU.0b013e3182393599. PMID: 22228332

9. Bongiovanni M., Paone G., Ceriani L. et al. Cellular and molecular basis for thyroid cancer imaging in nuclear medicine. Clin Transl Im 2013;1(3):149–61. DOI: 10.1007/s40336-013-0025-z.

Bongiovanni M., Paone G., Ceriani L. et al. Cellular and molecular basis for thyroid cancer imaging in nuclear medicine. Clin Transl Im 2013;1(3):149–61. DOI: 10.1007/s40336-013-0025-z.

10.

10. Заплатников К., Менцель К., Диль М. и др. Позитронно-эмиссионная томография с 18F-фтордезоксиглюкозой в ракурсе современной диагностики, диспансерного наблюдения и лечения дифференцированного рака щитовидной железы. Проблемы эндокринологии 2004;(1–2):46–50. [Zaplatnikov K., Mentsel’ K., Dil’ M. et al. Positron emission tomography with 18F-fluorodepxyglucose in current diagnostics, out-patient observation, and treatment of thyroid cancer. Problems of Endocrinology 2004; (1–2):46–50. (In Russ.)].

Заплатников К., Менцель К., Диль М. и др. Позитронно-эмиссионная томография с 18F-фтордезоксиглюкозой в ракурсе современной диагностики, диспансерного наблюдения и лечения дифференцированного рака щитовидной железы. Проблемы эндокринологии 2004;(1–2):46–50. [Zaplatnikov K., Mentsel’ K., Dil’ M. et al. Positron emission tomography with 18F-fluorodepxyglucose in current diagnostics, out-patient observation, and treatment of thyroid cancer. Problems of Endocrinology 2004; (1–2):46–50. (In Russ.)].

11.

11. Wadsak W., Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol 2010;73(3):461–9. DOI: 10.1016/j.ejrad.2009.12.022. PMID: 20181453

Wadsak W., Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol 2010;73(3):461–9. DOI: 10.1016/j.ejrad.2009.12.022. PMID: 20181453

12.

12. Joensuu H., Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28(5):910–4. PMID: 3572549.

Joensuu H., Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28(5):910–4. PMID: 3572549.

13.

13. Feine U., Lietzenmayer R., Hanke J.P. et al. Fluorine-18-FDG and iodine-131- iodide uptake in thyroid cancer. J Nucl Med 1996;37(9):1468–72. PMID: 8790195

Feine U., Lietzenmayer R., Hanke J.P. et al. Fluorine-18-FDG and iodine-131- iodide uptake in thyroid cancer. J Nucl Med 1996;37(9):1468–72. PMID: 8790195

14.

14. Seo Y.L., Yoon D.Y., Baek S. et al. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrastenhanced CT and (18)F- FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18) F- FDG PET/CT in recurrent thyroid cancer). Eur Radiol 2012;22(10):2246–54. DOI: 10.1007/s00330-012-2470-x. PMID: 22562091

Seo Y.L., Yoon D.Y., Baek S. et al. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrastenhanced CT and (18)F- FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18) F- FDG PET/CT in recurrent thyroid cancer). Eur Radiol 2012;22(10):2246–54. DOI: 10.1007/s00330-012-2470-x. PMID: 22562091

15.

15. Seo J.H., Lee S.W., Ahn B.C., Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) 2010;72(4):558–63. DOI: 10.1111/j.1365- 2265.2009.03693.x. PMID: 19744107

Seo J.H., Lee S.W., Ahn B.C., Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) 2010;72(4):558–63. DOI: 10.1111/j.1365- 2265.2009.03693.x. PMID: 19744107

16.

16. Hall N.C., Kloos R.T. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Arq Bras Endocrinol Metabol 2007;51(5):793–805. DOI: 10.1590/S0004- 27302007000500017. PMID: 17891243

Hall N.C., Kloos R.T. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Arq Bras Endocrinol Metabol 2007;51(5):793–805. DOI: 10.1590/S0004- 27302007000500017. PMID: 17891243

17.

17. O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010;15(2):146–56. DOI: 10.1634/theoncologist.2009-0190. PMID: 20142332

O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010;15(2):146–56. DOI: 10.1634/theoncologist.2009-0190. PMID: 20142332

18.

18. Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI: 10.1210/jc.2005-2838. PMID: 16684830

Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI: 10.1210/jc.2005-2838. PMID: 16684830

19.

19. Валдина Е.А. Заболевания щитовидной железы: Руководство. СПб.: Питер, 2006. [Valdina E.A. Thyroid disorders. Guidelines. Saint-Petersburg: Piter, 2006. (In Russ.)].

Валдина Е.А. Заболевания щитовидной железы: Руководство. СПб.: Питер, 2006. [Valdina E.A. Thyroid disorders. Guidelines. Saint-Petersburg: Piter, 2006. (In Russ.)].

20.

20. Schlumberger M.J. Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status. J Endocrinol Invest 1999;22(11 suppl): 3–7. PMID: 10726999

Schlumberger M.J. Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status. J Endocrinol Invest 1999;22(11 suppl): 3–7. PMID: 10726999

21.

21. Casara D., Rubello D., Saladini G. et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate analysis of prognostic variables. J Nucl Med 1993;34(10):1626–31. PMID: 8410272

Casara D., Rubello D., Saladini G. et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate analysis of prognostic variables. J Nucl Med 1993;34(10):1626–31. PMID: 8410272

22.

22. Schlumberger M.J., Arcangioli O., Piekarski J.D. et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988;29(11):1790–4. PMID: 3183748

Schlumberger M.J., Arcangioli O., Piekarski J.D. et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988;29(11):1790–4. PMID: 3183748

23.

23. King A.D. Imaging for staging and management of thyroid cancer. Cancer Imaging 2008;8:57–69. DOI: 10.1102/1470-7330.2008.0007. PMID: 18390389

King A.D. Imaging for staging and management of thyroid cancer. Cancer Imaging 2008;8:57–69. DOI: 10.1102/1470-7330.2008.0007. PMID: 18390389

24.

24. Kucuk O.N., Gultekin S.S., Aras G., Ibis E. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer. Nucl Med Commun 2006;27(3):261–6. PMID: 16479246

Kucuk O.N., Gultekin S.S., Aras G., Ibis E. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer. Nucl Med Commun 2006;27(3):261–6. PMID: 16479246

25.

25. Dietlein M., Scheidhauer K., Voth E. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24(11):1342–8. PMID: 9371865

Dietlein M., Scheidhauer K., Voth E. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24(11):1342–8. PMID: 9371865

26.

26. Salvatori M., Biondi B., Rufini V. Imaging in endocrinology: 2-[18F]-fluoro-2- deoxy-D- glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. Eur J Endocrinol 2015;173(3):R115–30. DOI: 10.1530/EJE-15-0066. PMID: 25947140

Salvatori M., Biondi B., Rufini V. Imaging in endocrinology: 2-[18F]-fluoro-2- deoxy-D- glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. Eur J Endocrinol 2015;173(3):R115–30. DOI: 10.1530/EJE-15-0066. PMID: 25947140

27.

27. Leboulleux S., Schroeder P.R., Busaidy N.L. et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009;94(4):1310–6. DOI: 10.1210/jc.2008-1747. PMID: 19158200

Leboulleux S., Schroeder P.R., Busaidy N.L. et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009;94(4):1310–6. DOI: 10.1210/jc.2008-1747. PMID: 19158200

28.

28. Padovani R.P., Robenshtok E., Brokhin M., Tuttle R.M. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 2012;22(8):778–83. DOI: 10.1089/thy.2011.0522. PMID: 22780333

Padovani R.P., Robenshtok E., Brokhin M., Tuttle R.M. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 2012;22(8):778–83. DOI: 10.1089/thy.2011.0522. PMID: 22780333

29.

29. Tuttle R.M., Tala H., Shah J. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20(12):1341–9. DOI: 10.1089/thy.2010.0178.

Tuttle R.M., Tala H., Shah J. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20(12):1341–9. DOI: 10.1089/thy.2010.0178.

30.

30. Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214. DOI: 10.1089/thy.2009.0110. PMID: 19860577

Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214. DOI: 10.1089/thy.2009.0110. PMID: 19860577

31.

31. Treglia G., Bertagna F., Piccardo A., Giovanella L. 131-I- whole-body scan or 18-FDG- PET/CT for patients with elevated thyroglobulin and negative ultrasound? Clin Translat Im 2013;1(3):175–83. DOI: 10.1007/s40336-013-0024-0.

Treglia G., Bertagna F., Piccardo A., Giovanella L. 131-I- whole-body scan or 18-FDG- PET/CT for patients with elevated thyroglobulin and negative ultrasound? Clin Translat Im 2013;1(3):175–83. DOI: 10.1007/s40336-013-0024-0.

32.

32. Leboulleux S., El Bez I., Borget I. et al. Postradioiodine treatment whole body scan in the era of fluorodesoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 2012;22(8):832–8. DOI: 10.1089/thy.2012.0081.

Leboulleux S., El Bez I., Borget I. et al. Postradioiodine treatment whole body scan in the era of fluorodesoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 2012;22(8):832–8. DOI: 10.1089/thy.2012.0081.

33.

33. Dong M.J., Liu Z.F., Zhao K. et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan. Meta-analysis. Nucl Med Commun 2009;30(8):639–50. DOI: 10.1097/MNM.0b013e32832dcfa7. PMID: 19512954

Dong M.J., Liu Z.F., Zhao K. et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan. Meta-analysis. Nucl Med Commun 2009;30(8):639–50. DOI: 10.1097/MNM.0b013e32832dcfa7. PMID: 19512954

34.

34. Kim W.G., Ryu J.S., Kim E.Y. et al. Empiric high-dose 131-Iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18-F-Fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab 2010;95(3):1169–73. DOI: 10.1210/jc.2009-1567.

Kim W.G., Ryu J.S., Kim E.Y. et al. Empiric high-dose 131-Iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18-F-Fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab 2010;95(3):1169–73. DOI: 10.1210/jc.2009-1567.

35.

35. Giovanella L. Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. Exp Rev Endocrinol Metab 2012;7(1):35–43. DOI: 10.1586/eem.11.83.

Giovanella L. Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. Exp Rev Endocrinol Metab 2012;7(1):35–43. DOI: 10.1586/eem.11.83.

36.

36. Pacak K., Eisenhofer G., Goldstein D.S. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25(4):568–80. DOI: 10.1210/er.2003-0032. PMID: 15294882

Pacak K., Eisenhofer G., Goldstein D.S. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25(4):568–80. DOI: 10.1210/er.2003-0032. PMID: 15294882

37.

37. Robbins R.J., Wan Q., Grewal R.K. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2- deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91(2):498–505. DOI: 10.1210/jc.2005-1534. PMID: 16303836

Robbins R.J., Wan Q., Grewal R.K. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2- deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91(2):498–505. DOI: 10.1210/jc.2005-1534. PMID: 16303836

38.

38. Deandreis D., Al Ghuzlan A., Leboulleux S. et al. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011;18(1):159–69. DOI: 10.1677/ERC-10-0233.

Deandreis D., Al Ghuzlan A., Leboulleux S. et al. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011;18(1):159–69. DOI: 10.1677/ERC-10-0233.

39.

39. Wang W., Larson S.M., Fazzari M. et al. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocr Metab 2000;85(3):1107–13. DOI: 10.1210/jcem.85.3.6458. PMID: 10720047

Wang W., Larson S.M., Fazzari M. et al. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocr Metab 2000;85(3):1107–13. DOI: 10.1210/jcem.85.3.6458. PMID: 10720047

40.

40. Pryma D.A., Schoder H., Gonen M. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 2006;47(8):1260–6. PMID: 16883003

Pryma D.A., Schoder H., Gonen M. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 2006;47(8):1260–6. PMID: 16883003

41.

41. Rosenbaum-Krumme S.J., Gorges R., Bockisch A., Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 2012;39(9):1373–80. DOI: 10.1007/s00259-012-2065-4. PMID: 22718304

Rosenbaum-Krumme S.J., Gorges R., Bockisch A., Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 2012;39(9):1373–80. DOI: 10.1007/s00259-012-2065-4. PMID: 22718304

42.

42. Gaertner F.C., Okamoto S., Shiga T. et al. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well- differentiated thyroid cancer than radioiodine uptake. Clin Nucl Med 2015;40(5):378–83. DOI: 10.1097/RLU.0000000000000699. PMID: 25608175

Gaertner F.C., Okamoto S., Shiga T. et al. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well- differentiated thyroid cancer than radioiodine uptake. Clin Nucl Med 2015;40(5):378–83. DOI: 10.1097/RLU.0000000000000699. PMID: 25608175

43.

43. Sisson J.C., Ackermann R.J., Meyer M.A., Wahl R.L. Uptake of 18-fluoro-2-deoxy- D- glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993;77(4):1090–4. DOI: 10.1210/jcem.77.4.8408458. PMID: 8408458

Sisson J.C., Ackermann R.J., Meyer M.A., Wahl R.L. Uptake of 18-fluoro-2-deoxy- D- glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993;77(4):1090–4. DOI: 10.1210/jcem.77.4.8408458. PMID: 8408458

44.

44. van Tol K.M., Jager P.L., Piers D.A. et al. Better yield of (18)fluorodeoxyglucosepositron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12(5):381–7. DOI: 10.1089/105072502760043459. PMID: 12097198

van Tol K.M., Jager P.L., Piers D.A. et al. Better yield of (18)fluorodeoxyglucosepositron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12(5):381–7. DOI: 10.1089/105072502760043459. PMID: 12097198

45.

45. Grunwald F., Biersack H.J. FDG PET in thyroid cancer: thyroxine or not? J Nucl Med 2000;41(12):1996–8. PMID: 11138684

Grunwald F., Biersack H.J. FDG PET in thyroid cancer: thyroxine or not? J Nucl Med 2000;41(12):1996–8. PMID: 11138684

46.

46. Marcus C., Whitworth P.W., Surasi D.S. et al. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol 2014;202(6):1316–29. DOI: 10.2214/AJR.13.11673.

Marcus C., Whitworth P.W., Surasi D.S. et al. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol 2014;202(6):1316–29. DOI: 10.2214/AJR.13.11673.

47.

47. Vural G.U., Akkas B.E., Ercakmak N. et al. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med 2012;37:953–9. DOI: 10.1097/RLU.0b013e31825b2057. PMID: 22899202

Vural G.U., Akkas B.E., Ercakmak N. et al. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med 2012;37:953–9. DOI: 10.1097/RLU.0b013e31825b2057. PMID: 22899202

48.

48. Zoller M., Kohlfuerst S., Igerc I. et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2007;34(4):487–95. DOI: 10.1007/s00259-006-0276-2. PMID: 17103166

Zoller M., Kohlfuerst S., Igerc I. et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2007;34(4):487–95. DOI: 10.1007/s00259-006-0276-2. PMID: 17103166

49.

49. Bertagna F., Bosio G., Biasiotto G. et al. F-18 FDGPET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med 2009; 34:756–61. DOI: 10.1097/RLU.0b013e3181b7d95c. PMID: 19851169

Bertagna F., Bosio G., Biasiotto G. et al. F-18 FDGPET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med 2009; 34:756–61. DOI: 10.1097/RLU.0b013e3181b7d95c. PMID: 19851169

50.

50. Schluter B., Bohuslavizki K.H., Beyer W. et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001;42(1):71–6. PMID: 11197983

Schluter B., Bohuslavizki K.H., Beyer W. et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001;42(1):71–6. PMID: 11197983

51.

51. Shammas A., Degirmenci B., Mountz J.M. et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic welldifferentiated thyroid cancer. J Nucl Med 2007;48(2):221–6. PMID: 17268018

Shammas A., Degirmenci B., Mountz J.M. et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic welldifferentiated thyroid cancer. J Nucl Med 2007;48(2):221–6. PMID: 17268018

52.

52. Bertagna F., Biasiotto G., Orlando E. et al. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative 131I scan: review of the literature. Jpn J Radiol 2010;28(9):629–36. DOI: 10.1007/s11604-010-0488-z.

Bertagna F., Biasiotto G., Orlando E. et al. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative 131I scan: review of the literature. Jpn J Radiol 2010;28(9):629–36. DOI: 10.1007/s11604-010-0488-z.

53.

53. Zimmer L.A., McCook B., Meltzer C. et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 2003;128(2):178–84. DOI: 10.1067/mhn.2003.74. PMID: 12601311

Zimmer L.A., McCook B., Meltzer C. et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 2003;128(2):178–84. DOI: 10.1067/mhn.2003.74. PMID: 12601311

54.

54. Giovanella L., Trimboli P., Verburg F.A. et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2013;40(6):874–80. DOI: 10.1007/s00259-013-2370-6. PMID: 2346330

Giovanella L., Trimboli P., Verburg F.A. et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2013;40(6):874–80. DOI: 10.1007/s00259-013-2370-6. PMID: 2346330

55.

55. Nanni C., Rubello D., Fanti S. et al. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 2006;60(8):409–13. DOI: 10.1016/j.biopha.2006.07.008. PMID: 16891093

Nanni C., Rubello D., Fanti S. et al. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 2006;60(8):409–13. DOI: 10.1016/j.biopha.2006.07.008. PMID: 16891093

56.

56. Palmedo H., Bucerius J., Joe A. et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47(4):616–24. PMID: 16595495

Palmedo H., Bucerius J., Joe A. et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47(4):616–24. PMID: 16595495